-+ 0.00%
-+ 0.00%
-+ 0.00%

The FDA Accepts And Grants Priority Review to AstraZeneca’s Supplemental Biologics License Application For Imfinzi (Durvalumab) Combined With Enfortumab Vedotin For Muscle-invasive Bladder Cancer Who Are Ineligible For Or Have Declined Cisplatin-based Chemotherapy

Benzinga·09/25/2026 10:00:57
语音播报

https://www.astrazeneca.com/media-centre/press-releases/2026/perioperative-imfinzi-plus-neoadjuvant-enfortumab-vedotin-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer.html